Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults
Authors
Keywords
-
Journal
DRUGS
Volume 74, Issue 11, Pages 1241-1252
Publisher
Springer Nature
Online
2014-07-08
DOI
10.1007/s40265-014-0256-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat
- (2014) Eve-Irene Lepist et al. KIDNEY INTERNATIONAL
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Dolutegravir in antiretroviral-naive adults with HIV-1
- (2013) Hans-Jürgen Stellbrink et al. AIDS
- Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572)
- (2013) Cindy Vavro et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
- (2013) Stephen Castellino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women
- (2013) Jessica L Adams et al. ANTIVIRAL THERAPY
- Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
- (2013) Mackenzie L. Cottrell et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
- (2013) Stephen Weller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing
- (2013) Benjamin N. Greener et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir
- (2013) F. Canducci et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics
- (2013) Shuguang Chen et al. PHARMACOGENOMICS
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
- (2013) Thibault Mesplède et al. Retrovirology
- A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects
- (2012) Justin Koteff et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients
- (2012) F. Saladini et al. CLINICAL MICROBIOLOGY AND INFECTION
- The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults
- (2012) Mark R. Underwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin
- (2012) Kelly E. Dooley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Effect of a Single Supratherapeutic Dose of Dolutegravir on Cardiac Repolarization
- (2012) Shuguang Chen et al. PHARMACOTHERAPY
- Assessing a Theoretical Risk of Dolutegravir-Induced Developmental Immunotoxicity in Juvenile Rats
- (2012) Melissa Rhodes et al. TOXICOLOGICAL SCIENCES
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience
- (2011) Carolina Garrido et al. ANTIVIRAL RESEARCH
- Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir
- (2011) Filippo Canducci et al. JOURNAL OF INFECTIOUS DISEASES
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More